Improved management of non-seminomatous testis tumors

J. P. Donohue, J. M. Perez, Lawrence Einhorn

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Two contributions to the management of non-seminomatous germinal tumors of the testis are reviewed. First, a midline technique of extended retroperitoneal lymph node dissection has been developed, allowing good access to both renal suprahilar zones as well as the traditional hilar and infrahilar areas. This technique has been used at our medical center to stage embryonal carcinoma or teratocarcinoma of the testis in patients who had negative preoperative chest tomography. Of 58 consecutive patients seen from 1965 to 1975, 30 had stage A disease and 28 had stage B. All 30 patients with stage A disease survived (100 per cent) and 24 of 28 patients with stage B disease survived (86 per cent), for an over-all survival rate of 93 per cent. The second contribution relates to the development of a new combination chemotherapy protocol for patients with stage C disease. Preoperative stage C lesions are treated with platinum, vinblastine sulfate and bleomycin. Patients who achieve clearance of pulmonary tumors but who have anatomic or serologic evidence of persistent retroperitoneal tumor after this chemotherapy are later treated with retroperitoneal lymph node dissection. Of 12 such patients 6 have been rendered free of tumor and now enjoy complete remission. Furthermore, 33 of 50 patients (66 per cent) with disseminated stage C disease achieved initial complete remission using this drug combination. Of the 50 patients 26 remain in continuous complete remission with no evidence of disease for 2 to 4 years, 7 are alive and in partial remission and 17 are dead. Improved chemotherapy opens alternative methods to manage advanced testis cancer.

Original languageEnglish
Pages (from-to)425-428
Number of pages4
JournalJournal of Urology
Volume121
Issue number4
StatePublished - 1979

Fingerprint

Testis
Neoplasms
Lymph Node Excision
Embryonal Carcinoma
Teratocarcinoma
Drug Therapy
Vinblastine
Bleomycin
Testicular Neoplasms
Drug Combinations
Combination Drug Therapy
Platinum
Thorax
Survival Rate
Tomography
Kidney
Lung

ASJC Scopus subject areas

  • Urology

Cite this

Donohue, J. P., Perez, J. M., & Einhorn, L. (1979). Improved management of non-seminomatous testis tumors. Journal of Urology, 121(4), 425-428.

Improved management of non-seminomatous testis tumors. / Donohue, J. P.; Perez, J. M.; Einhorn, Lawrence.

In: Journal of Urology, Vol. 121, No. 4, 1979, p. 425-428.

Research output: Contribution to journalArticle

Donohue, JP, Perez, JM & Einhorn, L 1979, 'Improved management of non-seminomatous testis tumors', Journal of Urology, vol. 121, no. 4, pp. 425-428.
Donohue, J. P. ; Perez, J. M. ; Einhorn, Lawrence. / Improved management of non-seminomatous testis tumors. In: Journal of Urology. 1979 ; Vol. 121, No. 4. pp. 425-428.
@article{833a6f97d2bb47268fe8282743bed63a,
title = "Improved management of non-seminomatous testis tumors",
abstract = "Two contributions to the management of non-seminomatous germinal tumors of the testis are reviewed. First, a midline technique of extended retroperitoneal lymph node dissection has been developed, allowing good access to both renal suprahilar zones as well as the traditional hilar and infrahilar areas. This technique has been used at our medical center to stage embryonal carcinoma or teratocarcinoma of the testis in patients who had negative preoperative chest tomography. Of 58 consecutive patients seen from 1965 to 1975, 30 had stage A disease and 28 had stage B. All 30 patients with stage A disease survived (100 per cent) and 24 of 28 patients with stage B disease survived (86 per cent), for an over-all survival rate of 93 per cent. The second contribution relates to the development of a new combination chemotherapy protocol for patients with stage C disease. Preoperative stage C lesions are treated with platinum, vinblastine sulfate and bleomycin. Patients who achieve clearance of pulmonary tumors but who have anatomic or serologic evidence of persistent retroperitoneal tumor after this chemotherapy are later treated with retroperitoneal lymph node dissection. Of 12 such patients 6 have been rendered free of tumor and now enjoy complete remission. Furthermore, 33 of 50 patients (66 per cent) with disseminated stage C disease achieved initial complete remission using this drug combination. Of the 50 patients 26 remain in continuous complete remission with no evidence of disease for 2 to 4 years, 7 are alive and in partial remission and 17 are dead. Improved chemotherapy opens alternative methods to manage advanced testis cancer.",
author = "Donohue, {J. P.} and Perez, {J. M.} and Lawrence Einhorn",
year = "1979",
language = "English",
volume = "121",
pages = "425--428",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Improved management of non-seminomatous testis tumors

AU - Donohue, J. P.

AU - Perez, J. M.

AU - Einhorn, Lawrence

PY - 1979

Y1 - 1979

N2 - Two contributions to the management of non-seminomatous germinal tumors of the testis are reviewed. First, a midline technique of extended retroperitoneal lymph node dissection has been developed, allowing good access to both renal suprahilar zones as well as the traditional hilar and infrahilar areas. This technique has been used at our medical center to stage embryonal carcinoma or teratocarcinoma of the testis in patients who had negative preoperative chest tomography. Of 58 consecutive patients seen from 1965 to 1975, 30 had stage A disease and 28 had stage B. All 30 patients with stage A disease survived (100 per cent) and 24 of 28 patients with stage B disease survived (86 per cent), for an over-all survival rate of 93 per cent. The second contribution relates to the development of a new combination chemotherapy protocol for patients with stage C disease. Preoperative stage C lesions are treated with platinum, vinblastine sulfate and bleomycin. Patients who achieve clearance of pulmonary tumors but who have anatomic or serologic evidence of persistent retroperitoneal tumor after this chemotherapy are later treated with retroperitoneal lymph node dissection. Of 12 such patients 6 have been rendered free of tumor and now enjoy complete remission. Furthermore, 33 of 50 patients (66 per cent) with disseminated stage C disease achieved initial complete remission using this drug combination. Of the 50 patients 26 remain in continuous complete remission with no evidence of disease for 2 to 4 years, 7 are alive and in partial remission and 17 are dead. Improved chemotherapy opens alternative methods to manage advanced testis cancer.

AB - Two contributions to the management of non-seminomatous germinal tumors of the testis are reviewed. First, a midline technique of extended retroperitoneal lymph node dissection has been developed, allowing good access to both renal suprahilar zones as well as the traditional hilar and infrahilar areas. This technique has been used at our medical center to stage embryonal carcinoma or teratocarcinoma of the testis in patients who had negative preoperative chest tomography. Of 58 consecutive patients seen from 1965 to 1975, 30 had stage A disease and 28 had stage B. All 30 patients with stage A disease survived (100 per cent) and 24 of 28 patients with stage B disease survived (86 per cent), for an over-all survival rate of 93 per cent. The second contribution relates to the development of a new combination chemotherapy protocol for patients with stage C disease. Preoperative stage C lesions are treated with platinum, vinblastine sulfate and bleomycin. Patients who achieve clearance of pulmonary tumors but who have anatomic or serologic evidence of persistent retroperitoneal tumor after this chemotherapy are later treated with retroperitoneal lymph node dissection. Of 12 such patients 6 have been rendered free of tumor and now enjoy complete remission. Furthermore, 33 of 50 patients (66 per cent) with disseminated stage C disease achieved initial complete remission using this drug combination. Of the 50 patients 26 remain in continuous complete remission with no evidence of disease for 2 to 4 years, 7 are alive and in partial remission and 17 are dead. Improved chemotherapy opens alternative methods to manage advanced testis cancer.

UR - http://www.scopus.com/inward/record.url?scp=0018761604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018761604&partnerID=8YFLogxK

M3 - Article

VL - 121

SP - 425

EP - 428

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4

ER -